On-line version ISSN 1806-4841
An. Bras. Dermatol. vol.80 no.5 Rio de Janeiro Sept./Oct. 2005
Double drainage to distinct lymphonodal basins detected by sentinel lymph node biopsy in cutaneous melanoma patients - Report of two cases*
Luiz Guilherme M. CastroI; João Pedreira DupratII; Gilles LandmanIII
ISupervising Physician - Doctor,
Dermatology Division, Hospital das Clínicas, Faculdade de Medicina, Universidade
de São Paulo (USP); Oncoderma - São Paulo (SP) Brazil
IIA.C. Camargo Treatment and Research Center at the Cancer Hospital; Oncoderma - São Paulo (SP) Brasil
IIIA.C. Camargo Treatment and Research Center at the Cancer Hospital - São Paulo (SP) Brasil
The main merits of sentinel lymph node biopsy in patients with cutaneous melanoma reside in the possibility of avoiding unnecessary radical nodectomies and of allowing a correct identification of the lymphatic draning basin, specially when the tumor is located in areas of ambiguous drainage. It is currently incorporated as a prognostic factor, being important for correct staging of the patient. This paper reports two cases in which the use of this technique was extremely useful, above all for having identified the presence of lymphatic drainage for two distinct basins. It is important for dermatologists to be aware of the correct indication of such technique, in order to guide patients in the best possible manner.
Keywords: Sentinel lymph node biopsy; Radionuclide imaging; Melanoma; Skin neoplasms; Medical oncology.
Sentinel lymph node biopsy technique (SLNB) has been increasingly employed in the treatment of cutaneous melanomas (CM). Although CM metastases are known to not always spread through the lymphatic route, because they may also use the blood stream to disseminate, and that other factors are likely to alter CM prognosis, which are facts that limit the absolute validity of BLNS as a predictive factor of evolution and survival, the method has undeniable advantages, which makes it an indication for an increasing number of CM patients.1,2 One of its main merits resides in the possibility of avoidance of unnecessary nodectomies.3,4 Correct identification of lymphatic draining basin is another strong point of the method, mainly when the tumor is located in areas of ambiguous drainage. This paper reports two cases in which the use of SLNB technique was extremely useful, above all for having identified the presence of lymphatic drainage for two distinct basins. Surgical approach of both basins would be, at least theoretically, more effective in detecting possible metastatic foci, thus allowing better staging and therapy.5
32 year-old female patient, referred to the service with recent history of a nevic lesion resection from anterior abdominal wall, immediately above the navel (Figure 1). Anatomopathological examination revealed an extensive superficial CM, with Breslow of 1 mm and Clark level III. There were no signs of regression, vascular or neural invasion. Physical examination revealed an obese patient, presenting hundreds of nevic lesions spread through all skin (Figures 1 and 2). Patient reported family history of CM (father), thus suggesting a case of familial atypical nevus syndrome. She presented a 3cm long linear scar, on the medial line of the abdominal wall, a few centimeters above the navel (Figure 1). No palpable lymph nodes were identified in any draining basins. SLNB and widening of melanoma margins were indicated. Scintigraphic study revealed drainage for both axillae, in a symmetrical fashion (Figure 3A), with two marked lymph nodes on the right.
Bilateral SLNB and widening of melanoma margins (1 cm) of the primary lesion were performed. Histopathological and immunohistochemical examination (HMB 45 and S100) of the sentinel nodes did not reveal a presence of metastatic cells. To our surprise, a new melanoma was detected in a nevic lesion located in the cranial portion of the scar of the first surgery (Figure 1). It was an in situ melanoma. Since the widening margin of the first melanoma already reached the 0.5 cm that are advocated for the treatment of a second in situ melanoma, a new widening was not needed. Patient completed 18 months of follow-up and is asymptomatic. Dermatoscopic follow-up of remaining lesions was requested. A later exeresis of more five lesions revealed atypical nevi.
41 year-old male patient, who had been followed in the service for years, because of basocellular carcinoma (BCC) and actinic keratoses. In a routine visit a nevic lesion was observed in left clavicular region, located about 3 cm above the scar of the previous BCC excision, four years earlier. Clinical hypothesis was of atypical nevus, indicating exeresis of the lesion. An excisional biopsy without safety margins was performed,. Anatomopathological examination revealed an extensive superficial CM, with Breslow 0.8 mm and Clark level III, in vertical growth stage. There were no signs of regression, vascular or neural invasion. No palpable lymph nodes were identified in any draining basins. According to the guidelines of the Grupo Brasileiro de Melanoma (GBM portuguese acronym for Brazilian Melanoma Group),6 SLNB and widening of surgical margins were both indicated. Scintigraphic study revealed double drainage to left axilla and left cervical regions (Figure 3B), being the drainage to the axilla more intense. SLNB of both lymph nodes and widening of margins (1 cm) of the primary lesion were performed. Histopathological and immunohistochemical examination (HMB 45 and S100) of the sentinel nodes did not reveal the presence of metastatic cells. Post-operatory period evolved with no intercurrences, and patient and family members were guided about the necessity of follow-up.
The possibility of lymphatic drainage to more than one lymph node basin and the presence of anomalous drainage are factors that may greatly compromise the efficacy of lymph nodectomy in the treatment of CM. The pattern of lymphatic drainage of certain skin areas is known to be quite variable, even when the well-known Sappey lines are used in clinical evaluation.7,8 Uncountable reports have demonstrated such variability, whereas others have demonstrated the existence of drainage to more than one lymph node basin, as occurred in the present case.5,7-10 This report reinforces the usefulness of SLNB technique in MC treatment. Most studies on this issue restrict the indication of SLNB to CM with Breslow thickness equal or greater than 1 mm; however, its utility for CMs with less than 1mm of Breslow thickness has been discussed, and up to 10% of patients with thickness between 0.76 and 1mm are known to have a possibility of presenting positivity in the assessment.6,11,12
Identification of a second melanoma in the same patient is not rare, mainly in persons with a great number of nevi, as occurred in the patient described in case 1.14 Family history, number of nevi and previous history of two melanomas make this patient have a high risk of developing new melanomas, demanding strict control of precursor lesions.15 q
1. Caraco C, Celentano F, Lastoria S, Botti G, Ascierto PA, Mozzillo N. Sentinel lymph node biopsy does not change melanoma-specific survival among patients with Breslow thickness greater than 4 mm. Ann Surg Oncol. 2004;11:198S-202S. [ Links ]
2. Thompson JF, Stretch JR, Uren RF, Ka VS, Scolyer RA. Sentinel node biopsy for melanoma: where have we been and where are we going? Ann Surg Oncol. 2004;11:147S-51S. [ Links ]
3. Cascinelli N, Santinami M, Maurichi A, Patuzzo R, Pennacchioli E. World Health Organization experience in the treatment of melanoma. Surg Clin North Am. 2003;83:405-16. [ Links ]
4. Leong SP. Selective sentinel lymphadenectomy for malignant melanoma. Surg Clin North Am. 2003;83:157-85. [ Links ]
5. Perrot RE, Glass F, Reintgen DS, Fenske NA. Reassessing the role of lymphatic mapping and sentinel lymphadenectomy in the management of cutaneous malignant melanoma. J Am Acad Dermatol. 2003;49:567-88. [ Links ]
6. Neves RI, Belfort FA, Brandão M, Silva DCP. Relatório final do consenso nacional sobre linfonodo sentinela (LNS) do Grupo Brasileiro de Melanoma. Acta Oncol Bras. 2003;23:499. [ Links ]
7. Uren RF, Howman-Giles R, Thompson JF. Patterns of lymphatic drainage from the skin in patients with melanoma. J Nucl Med. 2003;44:570-82. [ Links ]
8. Norman J, Cruse CW, Espinosa C, Clark R, Saba H, Wells K et al. Redefinition of cutaneous lymphatic drainage with the use of lymphoscintigraphy for malignant melanoma. Am J Surg. 1991;162:432-7. [ Links ]
9. Thompson JF, Uren RF, Shaw HM, Howman-Giles RB. Location of sentinel lymph nodes in patients with cutaneous melanoma: new insights into lymphatic anatomy. J Am Coll Surg. 1999;189:195-204. [ Links ]
10. Sumner WE 3rd, Ross MI, Mansfield PF, Lee JE, Pricto VG, Schacherer CW et al. Implications of lymphatic drainage to unusual sentinel lymph node sites in patients with primary cutaneous melanoma. Cancer. 2002;95:354-60. [ Links ]
11. Jacobs IA, Chang CK, Das Gupta TK, Salti GI. Role of Sentinel Lymph Node Biopsy in Patients With Thin (< 1 mm) Primary Melanoma. Ann Surg Oncol. 2003;10:558-61. [ Links ]
12. Lowe JB, Hurst E, Moley JF, Cornelius LA. Sentinel lymph node biopsy in patients with thin melanoma. Arch Dermatol. 2003;139:617-21. [ Links ]
13. Jansen L, Nieweg OE, Kapateijn AE, Valdes Olmos RA, Muller SH, Hoefragel CA et al. Reliability of lymphoscintigraphy in indicating the number of sentinel nodes in melanoma patients. Ann Surg Oncol. 2000;7:624-30. [ Links ]
14. Nashan D, Kocer B, Schiller M, Luger T, Grabbe S. Significant risk of a second melanoma in patients with a history of melanoma but no further predisposing factors. Dermatology. 2003;206:76-7. [ Links ]
15. Seykora J, Elder D. Dysplastic nevi and other risk markers for melanoma. Semin Oncol. 1996;23:682-7. [ Links ]
Luiz Guilherme M. Castro
Rua Mato Grosso, 128 cj 44 - Higienópolis
01239-040 - São Paulo - SP
Tel / Fax: (11) 3258-9990
Received on March 22, 2004.
Approved by the Consultive Council and accepted for publication on January 28, 2005.
* Work done at Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, A.C. Camargo Treatment and Research Center at the Cancer Hospital and at Oncoderma - São Paulo (SP) Brazil.